Abstract:Background: A single-dose varicella vaccine at 12 months of age was introduced to the National Immunization Program in February 2013 in Turkey. This study aimed to evaluate varicella-related hospitalization in children and the impact of a single-dose live attenuated varicella vaccine over the first 5.5 years of introducing a universal varicella vaccination. Methods: We analyzed data collected from the medical records of children <18 years old who required hospitalization due to varicella in 17 cities representing 50% of the childhood population in Turkey between 2008 and 2018. We calculated the rate of hospitalization for varicella per 100,000 children during the study period. The main objective of this study was to determine the yearly rate of hospitalization due to varicella and to compare these rates in the pre-vaccine and post-vaccine periods. The secondary objective was to compare demographic features, varicella-related complications, and outcomes between the pre-vaccine and post-vaccine periods. Results: A total of 4373 children (2458 boys and 1915 girls; 72.3% previously healthy) were hospitalized for varicella over a 10-year period, including 2139 children during the pre-vaccine period and 2234 children during the post-vaccine period. Overall, varicella hospitalization rates decreased significantly after the introduction of varicella vaccination [pre-vaccine vs. post-vaccine period; 3.79 vs. 2.87 per 100,000 per year; P < 0.001; odds ratio 0.75; 95% confidence interval 0.64–0.88]. The incidence of varicella-related hospitalization among children between 1 and 5 years of age was significantly lower in the post-vaccine era than in the pre-vaccine era, with a 60.2% decrease in hospitalizations (2.43 vs. 6.12 per 100,000 children; P < 0.001, odds ratio 0.39; 95% confidence interval 0.34–0.46). In both the 15-year-old groups ( P < 0.01 and P < 0.05). The mean age was higher during the post-vaccine period than during the pre-vaccine period ( P < 0.001). The absolute number of secondary bacterial infections ( P < 0.01), respiratory complications ( P < 0.01), and neurological complications ( P < 0.001) was significantly lower during the post-vaccine period. The incidence of severe varicella was lower during the post-vaccine period than during the pre-vaccine period ( P < 0.001). Conclusions: After 5.5 years of routine single-dose varicella vaccine use, we observed the impact of varicella vaccination on the incidence of varicella-related hospitalizations, especially in the target age group. However, we did not observe herd protection in the other age groups. The implementation of a second dose of the varicella vaccine in the National Immunization Program would help control disease activity.

Seroprevalence of varicella-zoster virus as measured by fluorescent antibody to membrane antigen assay and glycoprotein enzyme-linked immunosorbent assay more than 10 years after initiation of a universal vaccination program: An observational study

Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs

Analysis of antibody dynamics in Chinese children aged 1-3 years after single-dose varicella vaccination: A 42 months prospective study

Cross-sectional Study on Varicella Vaccination Efficacy in Children

Antibody Induced by One-Dose Varicella Vaccine Soon Became Weak in Children: Evidence from a Cross-Sectional Seroepidemiological Survey in Beijing, PRC

Varicella vaccination in Europe: are we ready for a universal childhood programme?

Epidemiology of varicella and effectiveness of varicella vaccine in Hangzhou, China, 2019

Long -term persistence of antibodies against varicella in fully immunized healthcare workers: an Italian retrospective cohort study

Vaccination Against Varicella Zoster Virus Infection in Less Developed Regions of Guangdong, China: A Cross-Sectional Serosurveillance Study

Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand

Study on Varicella-Zoster Virus Antibody Levels among Children Aged 1–7 Years in Changzhou, China

Impact of a 2-Dose Voluntary Vaccination Strategy on Varicella Epidemiology in Beijing, 2011-2017.

Reason for Outbreak of Varicella in Population after Immunization with a Single Dose of Varicella Vaccine

Expanded spectrum of varicella disease and the need for vaccination in India

Pediatric Varicella-related Hospitalization in Turkey Between 2008 and 2018: Impact of Universal Single Dose Varicella Vaccine (VARICOMP Study)

Efficacy of varicella (VZV) vaccination: an update for the clinician

Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States

Is chickenpox so bad, what do we know about immunity to varicella zoster virus, and what does it tell us about the future?

Survey of antibody levels to varicella-zoster virus in healthy population in Shanghai

A population database analysis to estimate the varicella vaccine effectiveness in children < 14 years in a high vaccination coverage area from 2004 to 2022

Varicella-zoster virus post-exposure management and prophylaxis: A review